Chi Sheng Pharma & Biotech (4111) Stock Overview
Manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
4111 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Chi Sheng Pharma & Biotech Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$30.40 |
| 52 Week High | NT$32.90 |
| 52 Week Low | NT$28.85 |
| Beta | 0.20 |
| 1 Month Change | 1.50% |
| 3 Month Change | 4.29% |
| 1 Year Change | 1.66% |
| 3 Year Change | 10.45% |
| 5 Year Change | 38.78% |
| Change since IPO | 138.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4111 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 2.7% | 0.3% | 0.9% |
| 1Y | 1.7% | -13.8% | 104.1% |
Return vs Industry: 4111 exceeded the TW Pharmaceuticals industry which returned -13.8% over the past year.
Return vs Market: 4111 underperformed the TW Market which returned 104.1% over the past year.
Price Volatility
| 4111 volatility | |
|---|---|
| 4111 Average Weekly Movement | 1.2% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in TW Market | 12.1% |
| 10% least volatile stocks in TW Market | 2.6% |
Stable Share Price: 4111 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4111's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | n/a | Dongmao Su | www.cscp.com.tw |
Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. Its product portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic agents; hormones and adrenal cortical steroids; autonomic nerve agents; antihistamines and antipruritics; antipyretics and analgesics; antitussives and anti-asthmatics; gastro-intestinal preparations; local anesthetic preparations; hemodialysis concentrate and external solutions; peritoneal dialysis solutions; and others. The company also offers medical devices, fat emulsion products, anesthetic products, hemostatic solutions, food and health food products, functional drinks, skin care products and cosmetics, and veterinary medicinal products.
Chi Sheng Pharma & Biotech Co., Ltd Fundamentals Summary
| 4111 fundamental statistics | |
|---|---|
| Market cap | NT$1.82b |
| Earnings (TTM) | NT$179.42m |
| Revenue (TTM) | NT$1.41b |
Is 4111 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4111 income statement (TTM) | |
|---|---|
| Revenue | NT$1.41b |
| Cost of Revenue | NT$845.39m |
| Gross Profit | NT$568.24m |
| Other Expenses | NT$388.82m |
| Earnings | NT$179.42m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.00 |
| Gross Margin | 40.20% |
| Net Profit Margin | 12.69% |
| Debt/Equity Ratio | 0.7% |
How did 4111 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/03 22:38 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chi Sheng Pharma & Biotech Co., Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaowei Huang | Masterlink Securities Investment Advisory |